Thyroid cancer: successful remnant ablation-what is success?
- PMID: 22751340
- DOI: 10.1038/nrendo.2012.113
Thyroid cancer: successful remnant ablation-what is success?
Comment on
-
Strategies of radioiodine ablation in patients with low-risk thyroid cancer.N Engl J Med. 2012 May 3;366(18):1663-73. doi: 10.1056/NEJMoa1108586. N Engl J Med. 2012. PMID: 22551127 Clinical Trial.
-
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.N Engl J Med. 2012 May 3;366(18):1674-85. doi: 10.1056/NEJMoa1109589. N Engl J Med. 2012. PMID: 22551128 Clinical Trial.
Similar articles
-
Radioiodine ablation in low-risk thyroid cancer.N Engl J Med. 2012 Aug 16;367(7):672; author reply 673-5. doi: 10.1056/NEJMc1206712. N Engl J Med. 2012. PMID: 22894582 No abstract available.
-
Radioiodine for thyroid cancer--is less more?N Engl J Med. 2012 May 3;366(18):1732-3. doi: 10.1056/NEJMe1202172. N Engl J Med. 2012. PMID: 22551133 No abstract available.
-
Well-being after radiation therapy in thyroid cancer.N Engl J Med. 2013 Feb 14;368(7):685-6. doi: 10.1056/NEJMc1212592. N Engl J Med. 2013. PMID: 23406048 No abstract available.
-
Recombinant human thyroid-stimulating hormone to stimulate 131-I uptake for remnant ablation and adjuvant therapy.Endocr Pract. 2013 Jan-Feb;19(1):149-56. doi: 10.4158/EP12278.RA. Endocr Pract. 2013. PMID: 23186980 Review.
-
[Current trends in treatment and follow-up of patients with differentiated thyroid carcinoma - experience with the use of recombinant human thyrotropin].Vnitr Lek. 2013 Feb;59(2):106-12. Vnitr Lek. 2013. PMID: 23461399 Review. Czech.
Cited by
-
Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses.J Endocrinol Invest. 2013 Nov;36(10):896-902. doi: 10.3275/8998. Epub 2013 May 30. J Endocrinol Invest. 2013. PMID: 23723055 Review.
-
Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.PLoS One. 2015 Mar 20;10(3):e0120184. doi: 10.1371/journal.pone.0120184. eCollection 2015. PLoS One. 2015. PMID: 25793762 Free PMC article.
-
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.Lancet Diabetes Endocrinol. 2019 Jan;7(1):44-51. doi: 10.1016/S2213-8587(18)30306-1. Epub 2018 Nov 27. Lancet Diabetes Endocrinol. 2019. PMID: 30501974 Free PMC article. Clinical Trial.
-
Strong Neck Accumulation of 131I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone.Medicine (Baltimore). 2015 Sep;94(39):e1490. doi: 10.1097/MD.0000000000001490. Medicine (Baltimore). 2015. PMID: 26426611 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical